Skip to main content

Table 4 Clinical data and laboratory tests in patients of the bleeding group categorized according to changes in serum sodium concentratio

From: Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis

Characteristics

Non-decreased (n = 58)

Decreased (n = 41)

p value

Age

53.66 ± 10.14

58.54 ± 12.20

0.039

Sex

  

0.167

 Male (%)

49 (84.5)

30 (73.2)

 

 Female (%)

9 (15.5)

11(26.8)

 

Etiology of cirrhosis

  

0.507

 Alcoholics (%)

35 (60.3)

22 (53.7)

 

 Non-alcoholics (%)

23 (39.7)

19 (46.3)

 

Infusion of albumin

  

0.282

 Yes (%)

20 (34.5)

10 (24.4)

 

 No (%)

38 (65.5)

31 (75.6)

 

Cumulative dose of Terlipressin (mg)

14.21 ± 3.42

14.80 ± 3.39

0.391

Amount of hydration (L)

4.34 ± 1.77

4.64 ± 2.13

0.447

Amount of sodium infused (mEq)

341.25 ± 259.89

313.77 ± 321.40

0.652

Total bilirubin (0 ~ 1.2 mg/dL)

3.72 ± 5.37

2.44 ± 2.63

0.122

Albumin (3.4 ~ 4.8 g/dL)

2.60 ± 0.49

2.75 ± 0.55

0.162

Creatinine (0.6 ~ 1.2 mg/dL)

1.17 ± 0.51

1.03 ± 0.47

0.163

Hemoglobin (13 ~ 17 g/dL)

8.64 ± 2.46

9.12 ± 2.28

0.328

*PT(0.8 ~ 1.2 *INR)

1.79 ± 0.61

1.58 ± 0.41

0.057

*MELD score

16.17 ± 7.63

13.66 ± 6.97

0.098

*MELD-Na

17.50 ± 12.67

12.93 ± 9.31

0.052

Child-Pugh score (6 ~ 18)

8.60 ± 1.75

7.61 ± 2.23

0.015

Initial sodium (135 ~ 145 mmol/L)

134.22 ± 4.93

137.91 ± 3.46

0.000

Lowest sodium (135 ~ 145 mmol/L)

133.21 ± 5.14

128.90 ± 5.20

0.000

  1. *PT, Prothrombin time; INR, International normalized ratio; MELD, Model for end-stage liver disease.